Orchestra BioMed Holdings, Inc. Ordinary Shares - $OBIO STOCK NEWS

Orchestra BioMed, a biomedical company, will host an R&D day in New York on June 11, 2024, to discuss their AVIM therapy program for hypertensive pacemaker patients. Key opinion leaders will present on the program's mechanism of action, clinical evidence, and study design.

Orchestra BioMed initiates enrollment of global pivotal study for AVIM therapy in hypertensive pacemaker patients with Medtronic collaboration. Financial results show expected cash runway into 2026. The company reports full year 2023 financial data and fourth quarter business update.

Orchestra BioMed appoints David Pacitti, President of Siemens Medical Solutions USA, to its Board of Directors. Mr. Pacitti brings extensive experience in cardiovascular devices and strategic partnerships, enhancing the company's leadership and connections in the medical device industry.

Orchestra BioMed announces positive pharmacokinetic data on Virtue SAB and favorable clinical results on AVIM therapy at CRT 2024 Meeting. Virtue SAB enables extended release of sirolimus without polymer degradation, while AVIM therapy shows long-term blood pressure reduction. The Company is collaborating with Medtronic for the BACKBEAT global pivotal study.

Orchestra BioMed Holdings, Inc. (OBIO) announced their participation in upcoming conferences in March 2024 to present high-impact technologies through risk-reward sharing partnerships. The company will be presenting at the Oppenheimer Annual Healthcare MedTech and Services Conference on March 12, 2024, and at the Barclays 26th Annual Global Healthcare Conference on March 14, 2024.

Orchestra BioMed announces positive clinical data on AVIM therapy for hypertensive pacemaker patients, showing significant reductions in blood pressure and favorable hemodynamic effects.

Orchestra BioMed announces significant long-term blood pressure reduction with AVIM therapy in hypertensive pacemaker patients. The MODERATO II study shows an 8.9 mmHg mean reduction in 24-hour ambulatory systolic blood pressure over 3.6 years. AVIM therapy aims to reduce blood pressure using a pacemaker. Orchestra BioMed collaborates with Medtronic for commercialization.

Orchestra BioMed Holdings, Inc. (OBIO) and Medtronic, Inc. (MDT) have announced an exclusive strategic collaboration for the development and commercialization of AVIM therapy for hypertensive pacemaker population, with the first patient randomized in the BACKBEAT pivotal study. The study aims to evaluate the efficacy and safety of AVIM therapy for the treatment of pacemaker-indicated patients with uncontrolled hypertension despite the use of antihypertensive medications. The study is a global, multi-center, prospective, randomized, double-blind study investigating the efficacy and safety of AVIM therapy in patients who have recently undergone implantation of a Medtronic dual-chamber cardiac pacemaker and have uncontrolled hypertension despite the use of antihypertensive medications. The primary efficacy endpoint will determine at three months post-randomization whether AVIM-treated patients experience a statistically significant reduction in daily average blood pressure (mean 24-hour ambulatory systolic blood pressure or “aSBP”) as compared to control patients. The primary safety endpoint will determine at three months post-randomization whether AVIM-treated patients experience serious adverse device effects that are not anticipated with cardiac pacing.

Orchestra BioMed (OBIO) announced FDA approval for pivotal studies of BackBeat CNT therapy in hypertensive pacemaker patients and Virtue SAB in coronary ISR patients. The company's third-quarter financial results revealed a cash runway until 2H 2026, with revenue and net loss details.